Skip to main content
Fig. 3 | Genome Medicine

Fig. 3

From: Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease

Fig. 3

Comparison of transcriptomic changes between infliximab and vedolizumab patients. A Cross-tabulation of genes differentially expressed in patients treated with infliximab (rows) and vedolizumab (columns) that achieved remission after 14 weeks of the respective therapy induction. The three groups of overlapping genes are highlighted in orange (group 1), green (group 2), and blue (group 3). B GO terms enriched in genes belonging to the three overlap groups. Dot size is proportional to the gene ratio and color corresponds to the p-value of enrichment. The top five GO terms in each group are visualized. C Heatmap showing average scaled mean expression counts at each time point of selected genes in the three overlap groups

Back to article page